Applied Dna Sciences INC 8-K Filing
Ticker: BNBX · Form: 8-K · Filed: May 1, 2024 · CIK: 744452
Sentiment: neutral
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-01 09:28:58
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm2413220d1_8k.htm (8-K) — 25KB
- tm2413220d1_ex99-1.htm (EX-99.1) — 27KB
- tm2413220d1_ex99x1x01.jpg (GRAPHIC) — 514KB
- tm2413220d1_ex99x1x02.jpg (GRAPHIC) — 570KB
- tm2413220d1_ex99x1x03.jpg (GRAPHIC) — 529KB
- tm2413220d1_ex99x1x04.jpg (GRAPHIC) — 471KB
- tm2413220d1_ex99x1x05.jpg (GRAPHIC) — 488KB
- tm2413220d1_ex99x1x06.jpg (GRAPHIC) — 248KB
- tm2413220d1_ex99x1x07.jpg (GRAPHIC) — 456KB
- tm2413220d1_ex99x1x08.jpg (GRAPHIC) — 394KB
- tm2413220d1_ex99x1x09.jpg (GRAPHIC) — 334KB
- tm2413220d1_ex99x1x10.jpg (GRAPHIC) — 337KB
- tm2413220d1_ex99x1x11.jpg (GRAPHIC) — 511KB
- tm2413220d1_ex99x1x12.jpg (GRAPHIC) — 397KB
- tm2413220d1_ex99x1x13.jpg (GRAPHIC) — 358KB
- tm2413220d1_ex99x1x14.jpg (GRAPHIC) — 397KB
- tm2413220d1_ex99x1x15.jpg (GRAPHIC) — 311KB
- tm2413220d1_ex99x1x16.jpg (GRAPHIC) — 343KB
- tm2413220d1_ex99x1x17.jpg (GRAPHIC) — 404KB
- tm2413220d1_ex99x1x18.jpg (GRAPHIC) — 273KB
- tm2413220d1_ex99x1x19.jpg (GRAPHIC) — 468KB
- 0001104659-24-055368.txt ( ) — 10980KB
- apdn-20240501.xsd (EX-101.SCH) — 3KB
- apdn-20240501_lab.xml (EX-101.LAB) — 33KB
- apdn-20240501_pre.xml (EX-101.PRE) — 22KB
- tm2413220d1_8k_htm.xml (XML) — 3KB
01
Item 7.01. Regulation FD Disclosure. On May 1, 2024, Applied DNA Sciences, Inc. (the "Company") utilized a company presentation which may be used in presentations to investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K is not incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing unless specifically stated so therein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Company Presentation, dated May 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 1, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer